PT - JOURNAL ARTICLE AU - Mahan Ghafari AU - Matthew Hall AU - Tanya Golubchik AU - Daniel Ayoubkhani AU - Thomas House AU - George MacIntyre-Cockett AU - Helen Fryer AU - Laura Thomson AU - Anel Nurtay AU - David Buck AU - Angie Green AU - Amy Trebes AU - Paolo Piazza AU - Lorne J Lonie AU - Ruth Studley AU - Emma Rourke AU - Darren Smith AU - Matthew Bashton AU - Andrew Nelson AU - Matthew Crown AU - Clare McCann AU - Gregory R Young AU - Rui Andre Nunes dos Santos AU - Zack Richards AU - Adnan Tariq AU - Roberto Cahuantzi AU - Wellcome Sanger Institute COVID-19 Surveillance Team AU - COVID-19 Infection Survey Group AU - The COVID-19 Genomics UK (COG-UK) Consortium AU - Jeff Barrett AU - Christophe Fraser AU - David Bonsall AU - Ann Sarah Walker AU - Katrina Lythgoe TI - High number of SARS-CoV-2 persistent infections uncovered through genetic analysis of samples from a large community-based surveillance study AID - 10.1101/2023.01.29.23285160 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.29.23285160 4099 - http://medrxiv.org/content/early/2023/01/30/2023.01.29.23285160.short 4100 - http://medrxiv.org/content/early/2023/01/30/2023.01.29.23285160.full AB - Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may act as viral reservoirs that could seed future outbreaks 1–5, give rise to highly divergent lineages 6–8, and contribute to cases with post-acute Coronavirus disease 2019 (COVID-19) sequelae (Long Covid) 9,10. However, the population prevalence of persistent infections, their viral load kinetics, and evolutionary dynamics over the course of infections remain largely unknown. We identified 381 infections lasting at least 30 days, of which 54 lasted at least 60 days. These persistently infected individuals had more than 50% higher odds of self-reporting Long Covid compared to the infected controls, and we estimate that 0.09-0.5% of SARS-CoV-2 infections can become persistent and last for at least 60 days. In nearly 70% of the persistent infections we identified, there were long periods during which there were no consensus changes in virus sequences, consistent with prolonged presence of non-replicating virus. Our findings also suggest reinfections with the same major lineage are rare and that many persistent infections are characterised by relapsing viral load dynamics. Furthermore, we found a strong signal for positive selection during persistent infections, with multiple amino acid substitutions in the Spike and ORF1ab genes emerging independently in different individuals, including mutations that are lineage-defining for SARS-CoV-2 variants, at target sites for several monoclonal antibodies, and commonly found in immunocompromised patients 11–14. This work has significant implications for understanding and characterising SARS-CoV-2 infection, epidemiology, and evolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe CIS was funded by the Department of Health and Social Care and the UK Health Security Agency with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) (grant code: MC_PC_19027), and Genome Research Limited, operating as the Wellcome Sanger Institute. The authors acknowledge use of data generated through the COVID-19 Genomics Programme funded by the Department of Health and Social Care. ASW is supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with the UK Health Security Agency (UK HSA) (NIHR200915) and the NIHR Oxford Biomedical Research Centre, and is an NIHR Senior Investigator. TH is supported by the Royal Society and Alan Turing Institute for Data Science and Artificial Intelligence. KAL is supported by the Royal Society and the Wellcome Trust (107652/Z/15/Z). The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The views expressed are those of the author and not necessarily those of the Department of Health and Social Care or UKHSA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data have been made publicly available as part of the COVID-19 Genomics UK (COG-UK) Consortium 51. All other data, excluding personal clinical information on participants, are available in the main text, supplementary materials, or our GitHub repository (https://github.com/mg878/ONS-CIS_analysis). https://github.com/mg878/ONS-CIS_analysis